Agilent Technologies Exceeds Q3 Fiscal 2026 Earnings Expectations
Agilent Technologies (NYSE:A) reported third-quarter fiscal 2026 revenue of $1.88 billion, surpassing expectations with core growth of 7.3%. Adjusted earnings per share were $1.56, up 14% year-over-year and exceeding the top end of its guidance range. The company's operating margin expanded to 27.2%, excluding tariff refunds, driven by improved market conditions and operational efficiencies from its Ignite Operating System. Growth was led by strong performance in pharmaceuticals (up 12%), China (9% growth), and applied markets. GLP-1-related revenue surged over 70%. Agilent also raised its full-year fiscal 2026 outlook, now expecting $7.49 billion to $7.51 billion in revenue with adjusted EPS of $6.12–$6.15. Management highlighted early pharmaceutical reshoring orders and a potential $1 billion opportunity through 2030. The company's Advanced Therapeutics division grew nearly 30%, supported by biotech demand, while diagnostics and clinical segments showed mixed results with growth of 6%. China outperformed expectations due to strong pharma and advanced materials sales.
Topics: china_market financial_results pharma_sector revenue_growth